Doximity vs Veeva

Doximity Faces Securities Fraud Class Action Lawsuit

Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Doximity, Inc. (NYSE: DOCS) for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint claims Doximity made false and misleading statements, overstating the positive impact of its Newsfeed product on revenue growth and misleading investors about its advertising delivery methods, which included banner ads and newsletters. The class period is from August 8, 2024, to May 13, 2026, with a deadline of November 16, 2026, for investors to seek lead plaintiff appointment. Investors who purchased shares during this period may be eligible for recovery.

• SBS files class action lawsuit against Doximity for securities fraud violations.
• Class period: August 8, 2024 to May 13, 2026.
• Deadline for lead plaintiff appointment: November 16, 2026.

Novant Health Partners with Doximity to Bring Evidence-Based Clinical AI Into Epic

Doximity announces new partnerships with Novant Health and Penn Highlands Healthcare to deploy its Clinical AI Suite, and releases the 2026 Physician Compensation Report highlighting AI fluency as a career advantage.

Penn Highlands Healthcare Partners with Doximity to Launch System-Wide Clinical AI Suite

Doximity announces a partnership with Penn Highlands Healthcare to deploy its Clinical AI Suite system-wide.

Omnicom Appoints Tom Schwenger CEO of Health Marketing

Omnicom (NYSE: OMC) has appointed Tom Schwenger as Chief Executive Officer of Omnicom Health's marketing business, effective immediately. Schwenger, who brings over 35 years of experience in pharma, biotech, and healthcare, will oversee the group's global marketing agencies. He succeeds Dana Maiman, who is leaving the company. Schwenger will work with Michael Larson, who remains Chairman of Omnicom Health and will also oversee the specialty health business. The appointment aims to drive accelerated growth, innovation, and AI adoption for clients amid rapid healthcare market evolution. Schwenger joins from Veeva Systems, where he served as President and Chief Customer Officer and tripled revenue. Previously, he spent nearly three decades at Accenture, leading its life sciences practice.

• Omnicom appointed Tom Schwenger as CEO of Omnicom Health's marketing business.
• Tom Schwenger previously served as President and Chief Customer Officer at Veeva Systems.
• Dana Maiman is leaving Omnicom Health after leading the unit.

Veeva Summit to Showcase Agentic AI and Data Innovations

Veeva Systems announced that leaders from AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche, UCB, and other biopharma companies will present new strategies for commercial and medical excellence at the Veeva Commercial Summit, Europe, scheduled for November 18-19, 2026, in Copenhagen. The summit will showcase how industry-specific AI enables sales, marketing, and medical teams to improve customer engagement, derive insights, and accelerate compliant content delivery. Key topics include agentic customer engagement, agentic CRM, agentic MLR for content approvals, and building a data foundation for AI with HCP access data and trusted data platforms. The event will feature over 100 sessions and 1,200+ industry experts, highlighting innovations with Veeva's Commercial Cloud and Data Cloud.

• Veeva Commercial Summit Europe is scheduled for November 18-19, 2026, in Copenhagen.
• The summit will feature over 100 sessions and 1,200+ industry experts.
• AstraZeneca, Bristol Myers Squibb, Grünenthal, Novo, Roche, and UCB will present case studies.

IQVIA Expands Veeva Partnership with Clinical Operations Applications

IQVIA and Veeva Systems announced an expansion of their partnership, with IQVIA selecting Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications for its clinical development studies. This extends the previously announced EDC partnership. The collaboration aims to increase trial speed and efficiency, strengthen site centricity, and improve decision-making for clinical research customers. All Veeva clinical solutions will also be available through IQVIA for sponsors seeking a full Veeva technology stack. Executives from both companies emphasized the benefits of integrated technologies and customer flexibility in choosing EDC, RTSM, and eCOA solutions. The announcement was made on October 13, 2026, ahead of the Veeva R&D and Quality Summit scheduled for October 20-21 in Boston.

• IQVIA selected Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standard applications.
• Partnership expansion extends the previously announced EDC partnership.
• All Veeva clinical solutions will be available through IQVIA for sponsors.